J Psychiatr Pract. 2024 Mar 1;30(2):82-94. doi: 10.1097/PRA.0000000000000776.
The two-injection start (TIS) initiation regimen was recently approved for aripiprazole once monthly 400 mg (AOM400), with potential benefits in adherence. The SaTISfy study described in this article analyzed Spanish psychiatrists' perspectives on hospitalization lengths of stay, schizophrenia management, and the use of AOM400-TIS.
The authors describe an ecological study of aggregated data collected using a 41-question survey. Fifty psychiatrists were asked to provide their perceptions of their patients with schizophrenia and treatment with AOM400.
The psychiatrists reported that lack of treatment adherence was the main reason for hospitalization for 58.3% of their patients diagnosed with schizophrenia. Aripiprazole, in any formulation, was the most commonly prescribed therapeutic option, being prescribed for a mean (SD) of 2.5 (0.9) out of 5 patients, while 98% of psychiatrists chose AOM400-TIS for patients who failed to adhere to previous treatments. Patients with schizophrenia, regardless of their treatment, were hospitalized for an average of 17.7 (3.93) days versus patients with schizophrenia treated with AOM400-TIS, who were hospitalized for an average of 14.2 (4.18) days, a reduction of 3.5 (3.86) days. Patients treated with AOM400-TIS showed a reduction of 5 (4.18) days compared with the mean national duration of hospitalization for acute patients in psychiatry units in Spain (19.18 d). The surveyed psychiatrists reported that AOM400-TIS improved safety and tolerability. Most of the psychiatrists were satisfied with the administration and results of AOM400-TIS. Most of the psychiatrists (90%) also reported that fewer health care resources were consumed with AOM400-TIS, mainly due to a reduction in hospitalization days and in the use of concomitant medications.
AOM400-TIS was considered to have a positive impact on the duration of hospitalization and thus on the use of health care resources. There was a positive perception of adherence, safety, and tolerability with the use of AOM400-TIS in patients with schizophrenia.
阿立哌唑每月 400 毫克（AOM400）的两针起始（TIS）给药方案最近获得批准，可能有助于提高用药依从性。本文所述的 SaTISfy 研究分析了西班牙精神科医生对住院时间、精神分裂症管理以及 AOM400-TIS 使用的看法。
作者描述了一项使用 41 个问题的调查进行的集合数据分析的生态学研究。50 名精神科医生被要求提供他们对精神分裂症患者及其 AOM400 治疗的看法。
精神科医生报告说，治疗依从性差是他们诊断为精神分裂症的 58.3%患者住院的主要原因。阿立哌唑，无论剂型如何，是最常开的治疗选择，平均每位患者处方 2.5（0.9）个选项，而 98%的精神科医生选择 AOM400-TIS 用于未遵守先前治疗的患者。无论治疗如何，精神分裂症患者的平均住院时间为 17.7（3.93）天，而接受 AOM400-TIS 治疗的精神分裂症患者的平均住院时间为 14.2（4.18）天，减少了 3.5（3.86）天。与西班牙精神病住院病房急性患者的全国平均住院时间（19.18 天）相比，接受 AOM400-TIS 治疗的患者减少了 5（4.18）天。接受调查的精神科医生报告称，AOM400-TIS 提高了安全性和耐受性。大多数精神科医生对 AOM400-TIS 的给药和结果感到满意。大多数精神科医生（90%）还报告说，AOM400-TIS 减少了医疗资源的消耗，主要是由于住院天数减少和同时使用的药物减少。
AOM400-TIS 被认为对住院时间有积极影响，从而对医疗资源的使用有积极影响。精神分裂症患者使用 AOM400-TIS 时，对依从性、安全性和耐受性的看法较为积极。
